July 16, 2017

Natural product therapy for CyclinD3-CDK6 overexpressing cancers: Luteolin, isolated from Salvia Tomentosa, increases the levels of tumor suppressor proteins, inhibits the activity of glycolytic enzymes 6-phosphofructokinase and pyruvate kinase M2, decreases antioxidants NADPH and glutathione levels, increases reactive oxygen species levels, promotes apoptosis, and inhibits the progression of CyclinD3-CDK6 overexpressing cancers via down regulation of its target gene, 17/July/2017, 12.10 am

Introduction: What they say A study from Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA; and Department of Genetics, Harvard Medical School, Boston, Massachusetts, USA shows […]
July 14, 2017

Natural product therapy for KRAS/LKB1-mutant lung cancer: Honokiol, isolated from Manolia Grandiflora(MG), increases the levels of tumor suppressor proteins, inhibits the expression of urea cycle enzyme carbamoyl phosphate synthetase-1 (CSP1), decreases pyrimidine pools, stalls DNA synthesis, and inhibits the progression of KRAS/LKB1-mutated lung cancers via up regulation of its target gene, 14/July/2017, 11. 58 pm

Introduction: What they say A study from the Children’s Medical Center Research Institute, UT Southwestern Medical Center, Dallas, Texas 75390, USA; Department of Pediatrics, UT Southwestern Medical Center, […]
July 13, 2017

Natural product-derived therapy for prostate cancer: Dihidromyricetin, isolated from Ampeopsis Grossdentatam, Japonica, andmegalophylla, among others, inhibits the expression of mTORC1 and its downstream target AMD1, dismantles mTORC1-AMD1 signaling network, decreases polyamine levels, and inhibits prostate cancer progression via up regualtion of its target gene, 13/July/2017, 10.19 am

Introduction: What they say: A study from CIC bioGUNE (Center for Cooperative Research in Biosciences), Bizkaia Technology Park, 801 Building, 48160 Derio, Spain shows that “mTORC1-dependent AMD1 regulation sustains polyamine […]
July 13, 2017

Natural product-based PD-1 pathway blockade for Human cancer therapy: Dihydroartemisinin (DHA), a derivative of Artemisinin isolated from Artemisia Annua L, decreases the expression of Glycogen synthase kinase-3β, increases transcription factor T-bet expression, decreases the abundance of co-inhibitory receptor PD-1 on the cell surface of Cytotoxic-T-cells, increases cytotoxic T lymphocyte function and augments anti-tumor activity, via up-regulation of its target gene, 13 July, 2017, 10.05 pm

Introduction:What they say:  A recent study from Cell Signalling Section, Division of Immunology, Department of Pathology, Tennis Court Road, University of Cambridge, Cambridge CB2 1QP, UK shows that “Glycogen Synthase […]